# US 2010/0143462 A1 · New carbamazephine formulations having inproved solubility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143462 A1
- Document ID: US20100143462A1
- Status: Published application
- Kind: A1
- Application number: 11/720,969
- Filed: 2005-12-06
- Published: 2010-06-10
- Earliest claimed: 2004-12-06
- Assignees: Nutralease Ltd.
- Inventors: Nissim Garti; Abraham Aserin; Anna Kogan
- Web page: https://patentgrep.com/patent/US20100143462A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to pharmaceutical compositions in the form of microcmulsions comprising carbamazcpinc and their enhanced permeability and extended release properties. The microcmulsion composition may be an oil based formulation or a oil/aqueous phase mixed formulation.

## Claims

### Claim 1

A microemulsion pharmaceutical composition comprising:
(i) Carbamazepine;
(ii) oil phase;
(iii) at least one C2-C5 alcohol as solvent; and
(iv) at least one non ionic surfactant.

### Claim 2 (depends on 1)

A microemulsion pharmaceutical composition according to claim 1, comprising 0.1-8 wt % carbamazepine, 10-25 wt % oil phase, 10-25 wt % of the at least one C2-C5 alcohol as solvent, and 50-70 wt % of said at least one non ionic surfactant.

### Claim 3 (depends on 1)

A microemulsion pharmaceutical composition according to claim 1 further comprising an aqueous phase.

### Claim 4 (depends on 3)

A microemulsion pharmaceutical composition according to claim 3 wherein the aqueous phase is selected from water or a mixture of water and C2-C5 alcohol as a co-solvent, said aqueous phase being up to 95 wt %.

### Claim 5 (depends on 1, 2, 3)

A microemulsion pharmaceutical composition according to claims 1-3 wherein the oil phase is selected from the group consisting of D-limonene, esterified compounds of fatty acids and primary alcohols, propylene glycol mono-C6-12 fatty acid esters, glycerol esters of carboxylic acids, medium chain triglycerides having 8 to 20 carbons, or their mixtures.

### Claim 6 (depends on 4)

A microemulsion pharmaceutical composition according to claim 4 wherein the C2-C5 alcohol is selected from mono hydroxyl alcohols selected from the group consisting of methanol, ethanol, propanol, butanol, pentanol, from bi- or tri-hydroxy alcohols selected from the group consisting of ethylene glycol and propylene glycol or their mixtures.

### Claim 7 (depends on 1)

A microemulsion pharmaceutical composition according to claim 1, wherein the non-ionic surfactant is selected from the group consisting of Brij 96, Tween 60, Tween 40 or Tween 80.

### Claim 8 (depends on 1, 2, 3)

A microemulsion pharmaceutical composition according to claims 1-3, further comprising an amphiphilic co-surfactant selected from the group consisting of non-ionic surfactants and alcohols, alkanoic acids, alkanediols and alkyl amines or their mixtures.

### Claim 9

A microemulsion pharmaceutical composition comprising:
(i) Carbamazepine;
(ii) oil phase selected from D-limonene or triacetin;
(iii) at least one C2-C5 alcohol as solvent;
(iv) an aqueous phase; and
(v) a non ionic surfactant selected from Brij 96, Tween 60 or Tween 80

### Claim 10 (depends on 9)

A pharmaceutical composition according to claim 9 wherein the aqueous phase is water or a mixture of water C2-C5 alcohol wherein the C2-C5 alcohol is selected from mono hydroxyl alcohols selected from the group consisting of methanol, ethanol, propanol, butanol, pentanol, from bi- or tri-hydroxy alcohols selected from the group consisting of ethylene glycol and propylene glycol or their mixtures.

### Claim 11 (depends on 9, 10)

A pharmaceutical composition according to claim 9 or 10, wherein the oil phase is selected from triacetin and vitamin E or D-limonene.

### Claim 12 (depends on 9, 10)

A pharmaceutical composition according to claim 9 or 10, wherein the oil phase is selected from triacetin and tocopherol acetate or D-limonene.

### Claim 13 (depends on 1, 9)

The composition of claim 1 or 9 wherein the formulation comprises thermodynamically stable molecular species having a diameter of between 10 to 100 nm.

### Claim 14 (depends on 1)

The pharmaceutical system of claim 1, wherein the at least one non-ionic surfactant is a non-ionic hydrophilic surfactant having an hydrophile-lipophile-balance (HLB) value greater than or equal to about 10.

### Claim 15 (depends on 14)

The pharmaceutical system of claim 14, wherein the non-ionic surfactant is selected from the group consisting of alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyethylene alkyl ethers; polyoxyethylene alkylphenols; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction products of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, and hydrogenated vegetable oils; sugar esters, sugar ethers; sucroglyccrides; and mixtures thereof.

### Claim 16 (depends on 14)

The pharmaceutical system of claim 14, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of polyoxyethylene alkylethers; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction products of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, and hydrogenated vegetable oils; and mixtures thereof.

### Claim 17 (depends on 16)

The pharmaceutical system of claim 16, wherein the non-ionic hydrophilic surfactant is the reaction product of a polyol and a monoglyceride, diglyceride, triglyceride, or a mixture thereof.

### Claim 18 (depends on 17)

The pharmaceutical system of claim 17, wherein the reaction product comprises a transesterification product.

### Claim 19 (depends on 17)

The pharmaceutical system of claim 17, wherein the polyol is glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, a saccharide, or a mixture thereof.

### Claim 20 (depends on 18)

The pharmaceutical system of claim 18, wherein the hydrophilic surfactant is selected from the group consisting of PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate monoglycerides, PEG-6 caprate/caprylate diglycerides, PEG-8 caprate/caprylate monoglycerides, PEG -8 caprate/caprylate diglycerides, polyglyceryl-10 laurate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, a poloxamer, and combinations thereof.

### Claim 21 (depends on 14)

The pharmaceutical system of claim 14, wherein the hydrophilic surfactant is selected from the group consisting of PEG-20 laurate, PEG-20 oleate, PEG-35 castor oil, PEG-40 palm kernel oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, polyglyceryl-10 laurate, PEG-6 caprate/caprylate monoglycerides, PEG-6 caprate/caprylate diglycerides, PEG-8 caprate/caprylate monoglycerides, PEG-8 caprate/caprylate diglycerides; polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, sucrose monostearate, sucrose monolaurate, a poloxamer, and combinations thereof.

### Claim 22 (depends on 14)

The pharmaceutical system of claim 14, wherein the hydrophilic surfactant is selected from the group consisting of PEG-35 castor oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate monoglycerides, PEG-6 caprate/caprylate diglycerides, PEG-8 caprate/caprylate monoglycerides, PEG-8 caprate/caprylate diglycerides, polysorbate 20, polysorbate 60, polysorbate 40, polysorbate 80, tocopheryl PEG-1000 succinate, a poloxamer, and combinations thereof.

### Claim 23 (depends on 1)

The pharmaceutical system of claim 1, substantially being free of water.

### Claim 24 (depends on 1)

The pharmaceutical system of claim 1 in the form of a preconcentrate in a liquid, or as an aqueous or organic diluted preconcentrate.

### Claim 25 (depends on 1)

The pharmaceutical system of claim 1, wherein the dosage form of the composition is a starch capsule, a cellulosic capsule, a hard gelatin capsule or a soft gelatin capsule.

### Claim 26 (depends on 1)

The pharmaceutical system of claim 1, wherein the dosage form is formulated for immediate release, controlled release, extended release, delayed release, targeted release, or targeted delayed release.

### Claim 27 (depends on 1)

The pharmaceutical system of claim 1, wherein the dosage form of the composition is a solution, spray, gel, drops, syrup or elixir.

### Claim 28 (depends on 1)

The pharmaceutical system of claim 1, enhancing two fold the permeability of Carbamazepine in comparison to the available commercial formulation Tegretol.

### Claim 29 (depends on 1, 9)

A method of increasing the bioavilability of Carbamazepine comprising administering the composition according to claim 1 or 9.

### Claim 30 (depends on 29)

The method of claim 29 wherein the composition is administered orally, topically, rectally, vaginally, parenterally, intramuscularly, intradermally, subcutaneously, intraparitoneally, or intravenously.
